A phase Ib clinical trial to compare the safety, tolerability, and immunogenicity of an HIV-1 adenoviral vector boost administered intramuscularly, intradermally, or subcutaneously after an HIV-1 DNA plasmid vaccine prime administered intramuscularly to healthy adenovirus type 5 seropositive HIV-1-uninfected adults.

Trial Profile

A phase Ib clinical trial to compare the safety, tolerability, and immunogenicity of an HIV-1 adenoviral vector boost administered intramuscularly, intradermally, or subcutaneously after an HIV-1 DNA plasmid vaccine prime administered intramuscularly to healthy adenovirus type 5 seropositive HIV-1-uninfected adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2015

At a glance

  • Drugs VRC-HIVADV014-00-VP (Primary) ; VRC-HIVADV014-00-VP (Primary) ; VRC-HIVADV014-00-VP (Primary) ; VRC-HIVDNA009-00-VP (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 May 2012 Planned end date (1 Nov 2008) added as reported by ClinicalTrials.gov.
    • 03 May 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top